Gabapentin GR: Phase III start

Next quarter, Depomed will begin the double-blind, placebo-controlled Phase III Breeze 2 trial to evaluate 1,200 mg Gabapentin GR given once daily, or 600 mg Gabapentin GR in the morning plus 1,200 mg...